These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 28004413)

  • 1. Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review.
    Owens RE; Kabra R; Oliphant CS
    Clin Cardiol; 2017 Jun; 40(6):407-412. PubMed ID: 28004413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?
    Anderson SL; Marrs JC
    Curr Cardiol Rep; 2019 Aug; 21(10):118. PubMed ID: 31473836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease.
    Briasoulis A; Inampudi C; Akintoye E; Alvarez P; Panaich S; Vaughan-Sarrazin M
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation).
    Thomas KL; Jackson LR; Shrader P; Ansell J; Fonarow GC; Gersh B; Kowey PR; Mahaffey KW; Singer DE; Thomas L; Piccini JP; Peterson ED
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29273635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease.
    Vinereanu D; Wang A; Mulder H; Lopes RD; Jansky P; Lewis BS; Gersh BJ; Avezum A; Hanna M; Held C; Wallentin L; Granger CB; Alexander JH
    Heart; 2018 Aug; 104(15):1292-1299. PubMed ID: 29352007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Safety and Effectiveness of Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation and Coexisting Valvular Heart Disease.
    Hampton ML; Tellor KB; Armbruster AL; Theodos G; Schwarze MW
    Am J Cardiovasc Drugs; 2020 Dec; 20(6):611-617. PubMed ID: 32043243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.
    Potpara TS; Lip GY; Larsen TB; Madrid A; Dobreanu D; Jędrzejczyk-Patej E; Dagres N;
    Europace; 2016 Oct; 18(10):1593-1598. PubMed ID: 27876696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease.
    Dawwas GK; Barnes GD
    Curr Cardiol Rep; 2022 Jun; 24(6):731-738. PubMed ID: 35460473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to define valvular atrial fibrillation?
    Fauchier L; Philippart R; Clementy N; Bourguignon T; Angoulvant D; Ivanes F; Babuty D; Bernard A
    Arch Cardiovasc Dis; 2015 Oct; 108(10):530-9. PubMed ID: 26184867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
    Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
    Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study.
    Al-Najar M; Al-Nusair M; Alrabadi N; Alawaisheh I; Alawaisheh T; Jarrah M; Alzoubi KH; Njem S; Hamoudeh A
    Vasc Health Risk Manag; 2023; 19():145-155. PubMed ID: 36968249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Valvular Heart Disease on Mortality, Thromboembolic and Cardiac Events in Japanese Patients With Atrial Fibrillation　- The Fushimi AF Registry.
    Doi K; Ogawa H; Ishigami K; Ikeda S; Aono Y; Hamatani Y; Fujino A; An Y; Ishii M; Iguchi M; Masunaga N; Esato M; Tsuji H; Wada H; Hasegawa K; Abe M; Akao M;
    Circ J; 2020 Apr; 84(5):714-722. PubMed ID: 32213725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Bioprosthetic Heart Valves.
    Duan L; Doctor JN; Adams JL; Romley JA; Nguyen LA; An J; Lee MS
    Am J Cardiol; 2021 May; 146():22-28. PubMed ID: 33529622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?
    Di Pasquale G; Zagnoni S; Riva L
    Intern Emerg Med; 2015 Feb; 10(1):21-4. PubMed ID: 25589164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study.
    Başaran Ö; Dogan V; Beton O; Tekinalp M; Aykan AÇ; Kalaycıoğlu E; Bolat I; Taşar O; Şafak Ö; Kalçık M; Yaman M; İnci S; Altıntaş B; Kalkan S; Kırma C; Biteker M;
    J Thromb Thrombolysis; 2017 Feb; 43(2):157-165. PubMed ID: 27848065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.